工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
GLUT5 装甲增强过继性 T 细胞疗法在葡萄糖限制条件下的抗肿瘤活性
英文原题：GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditions.
查看英文原题
GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
这种简单的修改与当前的临床方法兼容，并可能提高 T 细胞疗法治疗实体瘤的疗效。
研究思路结论见上方概要
背景
使用工程 T 细胞进行癌症免疫治疗已成为某些血液癌症的标准治疗方法。然而，实体瘤的临床试验结果明显滞后。实体瘤的主要挑战是由于血管化不良和与肿瘤细胞的竞争而导致肿瘤微环境中缺乏必需代谢物，例如葡萄糖。
方法
为了解决这个问题，我们通过引入异位 GLUT5 表达来修饰 T 细胞，以使用果糖作为替代能源。
结果
我们发现，用嵌合抗原受体 (CAR) 或异位 T 细胞受体 (TCR) 改造的“GLUT5 装甲”T 细胞，在体外和体内模型中的低血糖环境中均可实现增强的抗肿瘤活性。
展开英文摘要原文
BACKGROUND
Cancer immunotherapy with engineered T cells has become a standard treatment for certain haematological cancers. However, clinical trial outcomes for solid tumours are significantly lagging. A primary challenge in solid tumours is the lack of essential metabolites in the tumour microenvironment, such as glucose, due to poor vascularization and competition with tumour cells.
METHODS
To address this, we modified T cells to use fructose as an alternative energy source by introducing ectopic GLUT5 expression.
RESULTS
We show that "GLUT5-armored" T cells, engineered with either chimeric antigen receptors (CARs) or an ectopic T-cell receptor (TCR), achieve enhanced anti-tumour activity in low-glucose environments in both in vitro and in vivo models.
CONCLUSION
This straightforward modification is compatible with current clinical approaches and may improve the efficacy of T-cell therapies for solid tumours.
论文信息
- 作者
- Page R、Martinez O、Larcombe-Young D、Bugallo-Blanco E、Papa S、Perucha E
- 第一作者单位
- School of Cancer and Pharmaceutical Studies, King's College London SE1 9RT, United Kingdom.United Kingdom
- 通讯作者单位
- Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London.United Kingdom
- 期刊
- Immunotherapy advances2025
- 原文标识
- PubMed 40575013 · DOI 10.1093/immadv/ltaf018
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →